SCHEMBL18830045

SCHEMBL18830045

Cc1ccc2cc(-n3nnc4cnc(NC5CCCC5)nc43)ccc2n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK6 Q16659 10/20 0.54
▸ GSK3A P49840 3/20 0.53
▸ GSK3B P49841 3/20 0.53
▸ MAPK8 P45983 3/20 0.41
▸ MAPK9 P45984 3/20 0.41
▸ MAPK10 P53779 2/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CCND2 P30279 1/20 0.41
▸ CCND3 P30281 1/20 0.41
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ EIF2AK4 Q9P2K8 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ TP53 P04637 2/20 0.39
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18830178 0.99 MAPK6 (0.53) MAPK6GSK3AGSK3BMAPK8MAPK9
Carbamic Acid SCHEMBL18813041 0.94 MAPK6 (0.56) MAPK6GSK3AGSK3BMAPK8MAPK9
Carbamic Acid SCHEMBL18813046 0.93 MAPK6 (0.55) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL18813076 0.89 MAPK6 (0.49) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL18830319 0.88 MAPK6 (0.54) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL18813081 0.88 GSK3A (0.55) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL16012659 0.88 GSK3A (0.59) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL16014900 0.88 MAPK6 (0.68) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL17435275 0.88 GSK3A (0.59) MAPK6GSK3AGSK3BMAPK8MAPK9
SCHEMBL16012173 0.88 MAPK6 (0.48) MAPK6GSK3AGSK3BMAPK8EIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9855268-B2 Triazolo[4,5-d]pyrimidine derivatives MERCK PATENT GMBH (DE) 2018-01-02 — — US disclosed
EP-2964649-B1 TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2017-05-10 — — EP disclosed
US-20160015712-A1 Triazolo[4,5-d]pyrimidine derivatives MERCK PATENT GMBH (DE) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015712-A1 Triazolo[4,5-d]pyrimidine derivatives EIF2AK4, GCN1, GTF2I MAPK6 2535/4885GSK3A 3256/4885GSK3B 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback